Alumis Inc.
ALMSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Alumis Inc. (ALMS) is listed under Biotechnology. The company carries a $2.75B market cap, placing it firmly in the mid-cap category. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Market Cap
$2.75B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.31
EPS (TTM)
$-1.78
EPS (Fwd)
$-2.95
ROE
-64.6%
ROA
-58.8%
Cash
$522.9M
Total Debt
$35.7M
Free CF
-$206.8M
52W Change
556.5%
Annual Financials
Cash vs Debt
Alumis Inc. holds $522.9M in cash against $35.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$206.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -64.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alumis Inc.'s trajectory.